Cutting-edge technology now available in Mobius® 3D process containers Provides 10 times greater abrasion resistance compared to other single-use bi...
Expanded facility to manufacture mRNA-based therapies and vaccines Researchers at the University of Adelaide will address the design and manufacturi...
Triple quadrupole mass spectrometers (LC/MS/MS) are established in labs dealing with challenging matrices, as they offer very low detection limits with spe...
A balanced microbiome plays an important role in maintaining human health by promoting protective immune responses and limiting excessive inflammation. But...
Several of the tests are Research Use Only (RUO) such as the RUO LENA Q51® introduced by Alercell in January 2023. LENA Q51® is the most comprehens...
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Revenue Up 5.8% Year-Over-Year to RMB8,964 MillionNet Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 MillionDiluted ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QIAstat-Dx syndromic testing solution is expected to be available soon for use ...
-Virios’ IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program...
Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editi...
CVL is the most comprehensive cardiovascular platform in the country. By partnering with CVL, FCCI will join a network of leading practices across the coun...
The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial olig...
The expansion project aims to (i) grow Virica’s bioprocessing capacity to keep pace with client demand for scaling up viral medicines, (ii) advance n...
Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in...
© 2025 Biopharma Boardroom. All Rights Reserved.
